Safety and Efficacy Clinical Trial
Official title:
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | December 2023 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Multiple myeloma patients eligible for auto-HSCT. - High risk multiple myeloma (R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). - Expected survival = 3 months. - Creatinine < 2.0 mg/dl. - Blood coagulation function: PT and APTT <2x normal. - Arterial blood oxygen saturation>92%. - ALT(alanine aminotransferase)/AST (aspartate aminotransferase)< 3x normal - Karnofsky scores = 60 and ECOG score=2. - Adequate venous access for apheresis, and no other contraindications for leukapheresis. - Patients should not take immunotherapy in three months prior to CART cells infusion. - Voluntary informed consent is given. Exclusion Criteria: - Pregnant or lactating women. - Uncontrolled active infection. - Active hepatitis B or hepatitis C infection. - Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary. - Previously treatment with any gene therapy products. - Any uncontrolled active medical disorder that would preclude participation as outlined. - HIV infection. - History of myocardial infarction and severe arrhythmia in half a year. - Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease). - Patients with fever of unknown origin (T>38?). |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital, Soochow University | Suzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Soochow University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of adverse events | Proportion of subjects with adverse events overall and by severity grade | Approximately 3 years | |
Primary | PFS | Is defined as time from first induction date to first documentation of PD, or death due to any cause, whichever occurs first. | Minimum of 2 years after first induction | |
Primary | OS | Is defined as time from first induction date to time of death due to any cause | Minimum of 2 years after first induction | |
Secondary | Duration of best response | According to IMWG response criteria at the end of the research. | Minimum of 2 years | |
Secondary | MRD negative conversion ratio and persistence | MRD negative by flow cytometry | Minimum of 2 years | |
Secondary | Proportion of subjects who achieved Complete Response (CR) Rate | Percentage of subjects who achieved CR or stringent CR according to IMWG Uniform Response Criteria for Multiple Myeloma | Minimum of 2 years | |
Secondary | Pharmacokinetics - Cmax | Maximum transgene level | Approximately 2.5 years after first CAR infused | |
Secondary | Pharmacokinetics - Tmax | Time to peak transgene level | Approximately 2.5 years after first CAR infused | |
Secondary | Pharmacokinetics - AUC | Area under the curve of the transgene level | Approximately 2.5 years after first CAR infused | |
Secondary | Duration of persistence of CAR T cells in the blood | Duration of persistence of CAR T cells in the blood | Approximately 2.5 years after first CAR infused |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994210 -
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
|
Phase 2 | |
Terminated |
NCT05247957 -
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
N/A | |
Completed |
NCT04621123 -
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
|
Phase 2 | |
Recruiting |
NCT05140616 -
Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
|
Phase 1/Phase 2 | |
Recruiting |
NCT05349552 -
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
|
||
Completed |
NCT03820596 -
Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL
|
Phase 1/Phase 2 | |
Completed |
NCT02018250 -
Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)
|
Phase 1 | |
Recruiting |
NCT04446806 -
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
|
Phase 4 | |
Recruiting |
NCT05556889 -
Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block
|
N/A | |
Not yet recruiting |
NCT06244537 -
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
|
N/A | |
Completed |
NCT04785170 -
Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals
|
N/A | |
Recruiting |
NCT04677452 -
Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
|
Phase 1 | |
Completed |
NCT01305044 -
The HEALS Project - Health Education and Active Living for Surviving Seniors
|
Phase 2 | |
Active, not recruiting |
NCT04646590 -
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
|
Phase 3 | |
Recruiting |
NCT05021276 -
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
|
Phase 4 | |
Not yet recruiting |
NCT05008666 -
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
|
Phase 2 | |
Recruiting |
NCT06066840 -
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
|
Phase 4 | |
Active, not recruiting |
NCT04852068 -
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
|
Phase 3 |